Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Cancer · Renal Cell Carcinoma (RCC) · Pancreatic Neuroendocrine Tumors (pNET) · Extra-Pancreatic NET (epNET) · Hepatocellular Carcinoma (HCC) · Differentiated Thyroid Cancer (DTC) · Non-Clear Cell Renal Cell Carcinoma (nccRCC) · Colorectal Cancer · Prostate Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.5
3 insiders sold shares within a month
Since May 26, 2026 · was worth 10, fading over time
Score over time
- Stage
- Phase 3
- Patients
- 5,000 (planned)
- Started
- Jul 30, 2026
- Main results expected
- May 31, 2030
- Fully finished
- May 31, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Measured over: Up to 4 years (until the event resolves, returns to baseline, stabilizes, a new anticancer therapy is initiated, or the participant is lost to follow-up or withdraws consent, whichever occurs first)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.5, since 2026-05-26, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07620574 · record last updated 2026-10-28 · checked 2026-11-09 15:47 UTC